Cassava Sciences announced Thursday that the Department of Justice has concluded its investigation into the company over research misconduct allegations. The probe centered on the company's experimental Alzheimer's treatment simufilam.

Cassava Sciences announced Thursday that federal investigators have wrapped up their examination of the company following accusations of research misconduct related to its experimental Alzheimer’s treatment, simufilam.
The biotechnology firm revealed that the Department of Justice concluded its investigation four months following the dismissal of criminal charges in Maryland against Hoau-Yan Wang, a medical professor and former company consultant. Wang had been accused of providing fraudulent data concerning the Alzheimer’s drug.
The closure of the federal investigation marks the end of scrutiny that had surrounded the company’s research practices and the development of its potential Alzheimer’s therapy.
Hungarian Winger Daniel Salloi Moves from Kansas City to Toronto FC
TV Star Eric Dane Dies at 53 After Battle with ALS
Phoenix Suns Guard Devin Booker Sidelined with Hip Injury Against Spurs
Argentina’s Congress Advances Controversial Labor Reforms Despite Strike